 |
市场调查报告书
商品编码
1349941
造血干细胞移植(HSCT)市场:各移植类型，各适应症，各用途，各终端用户，各地区-规模，占有率，展望，机会分析，2023年～2030年Hematopoietic stem cell transplantation market, By Transplant Type, By Indication, By Application, By End User, By Region -Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
价格
简介目录
2023年全球造血干细胞移植（HSCT）市场规模预估为28.8亿美元，预测期间（2023-2030年）复合年增长率为11.2%。
| 报告范围 | 报告详细资料 | ||
|---|---|---|---|
| 基准年 | 2022 | 2023 年市场规模 | 美国：28.8亿美元 |
| 过去的资料 | 2018年至2021年 | 预测期间 | 2023-2030 |
| 预测 2023-2030 年复合年增长率： | 11.20% | 2030年价值预测 | 60.5亿美元 |
造血细胞移植（也称为骨髓移植或干细胞移植）是癌症（和其他一些疾病）的一种治疗方法。确认骨髓的正常功能可能有助于了解干细胞移植。造血细胞移植是治疗癌症最有效的方法。其他治疗，例如化疗和放射治疗，对骨髓有毒。一般来说，剂量越高，骨髓毒性越大。
造血细胞移植主要有两种：自体移植和同种异体移植。在自体移植中，患者自身的造血干细胞在大剂量化疗或放疗之前被取出，并冷冻保存以备后用。化疗或放射治疗结束后，收集的细胞被解冻并返回给患者。在同种异体移植中，造血干细胞取自捐赠者，最好是具有相似基因组成的兄弟姊妹。
市场动态
增加有机成长策略，例如主要市场进入者推出产品以扩大其产品组合，预计将在预测期内推动市场成长。例如，2020年1月，基因治疗产品提供者Bluebird Bio, Inc.推出了一项针对12岁及以上输血依赖性热贫血症（TDT）患者进行造血干细胞（HSC）移植的一次性基因治疗计画。推出ZYNTEGLO（编码Hui A-T87Q-珠蛋白基因的自体CD34+ 细胞）。ZYNTEGLO 的官方通用名称是基因工程自体 CD34+ 细胞富集群，其中含有编码 Hui A-T87Q-球蛋白基因的慢病毒载体转导的造血干细胞。
本调查的主要特征
- 本报告提供以2022年为基准年的预测期间（2023-2030 年）之全球造血干细胞移植(HSCT)市场的市场规模和復合年增长率（CAGR %）相关的详区隔析。
- 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
- 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
- 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球造血干细胞移植(HSCT)市场的主要参与者之企业简介。
- 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
- 全球造血干细胞移植(HSCT)市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
- 利益相关者可以透过全球造血干细胞移植(HSCT)市场用于分析的各种战略矩阵来帮助他们更容易做下决策。
目录
第1章 调查目的与前提条件
- 调查目的
- 前提条件
- 简称
第2章 市场概况
- 报告概要
- 市场定义和范围
- 摘要整理
第3章 市场动态，法规，趋势分析
- 市场动态
- 促进因素
- 阻碍因素
- 市场机会
- 影响分析
- 最近的检验药上市
- 流行病学
- 合併，收购，联盟
- 法规情势
- 主要的发展
- PEST分析
第4章 全球造血干细胞移植(HSCT)市场-COVID-19影响分析
- 经济影响
- COVID-19流行病学
- 供需的影响
第5章 造血干细胞移植(HSCT)的全球市场:各移植类型，2018年-2030年
- 同类移植
- 自体移植
第6章 造血干细胞移植(HSCT)的全球市场:适应各疾病，2018年～2030年
- 急性骨髓性白血病(AML)
- 急性淋巴芽球性白血病(ALL)
- 何杰金氏淋巴瘤(HL)
- 非何杰金氏淋巴瘤(NHL)
- 多发性骨髓瘤(MM)
- 其他
第7章 造血干细胞移植(HSCT)的全球市场，各用途，2018年～2030年
- 骨髓移植(BMT)
- 週边血液干细胞移植(PBSCT)
- 脐带血移植(CBT)
第8章 造血干细胞移植(HSCT)的全球市场:各终端用户，2018年～2030年
- 医院
- 专门诊所
- 其他
第9章 造血干细胞移植(HSCT)的全球市场:各地区，2018年～2030年
- 北美
- 美国
- 加拿大
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他南美国家
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 中东
- GCC
- 以色列
- 其他中东
- 非洲
- 北非
- 中非
- 南非
第10章 竞争情形
- 企业简介
- Pluristem Therapeutics Inc.
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Kiadis Pharma
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio,Inc.
- Talaris Therapeutics, Inc.,
- Marker Therapeutics Inc.
- Stempeutics Research Pvt Ltd.
- CBR Systems Inc.
- Priothera Ltd.
- Eurobio Scientific Group
- Otsuka America Pharmaceutical, Inc.
- Pfizer Inc.
- Sanofi
- FUJIFILM Holdings Corporation
第11章 章节
- 参考文献
- 调查手法
简介目录
Product Code: CMI1250
The global hematopoietic stem cell transplantation (HSCT) market is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11.2% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 2.88 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 11.20% | 2030 Value Projection: | US$ 6.05 Bn |
Hematopoietic cell transplantation (also called bone marrow transplantation or stem cell transplantation) is a type of treatment for cancer (and a few other conditions as well). A review of the normal function of the bone marrow will help in the understanding of stem cell transplantation. Hematopoietic cell transplantation is the most effective treatment for cancer. Other treatments, such as chemotherapy and radiation, are toxic to the bone marrow. In general, the higher the dose, the more toxic the effects on the bone marrow.
There are two main types of hematopoietic cell transplantation: autologous and allogeneic. In autologous transplantation, the patient's own hematopoietic stem cells are removed before high-dose chemotherapy or radiation is given, and they are then frozen for storage and later use. After chemotherapy or radiation is complete, the harvested cells are thawed and returned to the patient. In allogeneic transplantation, the hematopoietic stem cells come from a donor, ideally a brother or sister with a similar genetic makeup.
Market Dynamics
The increasing organic growth strategies, such as product launches by key market players to expand their product portfolio are expected to drive market growth over the forecast period. For instance, in January 2020, Bluebird Bio, Inc., a company providing gene therapy products, announced the launch of ZYNTEGLO (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for patients 12 years of age and older with transfusion-dependent β-thalassemia (TDT) for hematopoietic stem cell (HSC) transplantation in Germany. The full common name for ZYNTEGLO is a genetically modified autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with a lentiviral vector encoding the βA-T87Q-globin gene.
Key features of the study:
- This report provides an in-depth analysis of the global hematopoietic stem cell transplantation (HSCT) market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hematopoietic stem cell transplantation (HSCT) market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global hematopoietic stem cell transplantation (HSCT) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hematopoietic stem cell transplantation (HSCT) market
Detailed Segmentation:
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market , By Transplant Type:
- Allogeneic
- Autologous
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication:
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Hodgkin lymphoma (HL)
- Non-Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Others
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application:
- Bone Marrow Transplant (BMT)
- Peripheral Blood Stem Cells Transplant (PBSCT)
- Cord Blood Transplant (CBT)
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User:
- Hospitals
- Specialty Clinics
- Others
- Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pluristem Therapeutics Inc.
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Kiadis Pharma
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio, Inc.
- Talaris Therapeutics, Inc.
- Marker Therapeutics Inc.
- Stempeutics Research Pvt Ltd.
- CBR Systems Inc.
- Priothera Ltd.
- Eurobio Scientific Group
- Otsuka America Pharmaceutical, Inc.
- Pfizer Inc.
- Sanofi
- FUJIFILM Holdings Corporation
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Transplant Type
- Market Snippet, By Indication
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Hematopoietic Stem Cell Transplantation (HSCT) Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2018- 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Allogeneic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Autologous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Acute Myeloid Leukemia (AML)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Acute Lymphoblastic Leukemia (ALL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Hodgkin lymphoma (HL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Non-Hodgkin Lymphoma (NHL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Multiple Myeloma (MM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Bone Marrow Transplant (BMT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Peripheral Blood Stem Cells Transplant (PBSCT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Cord Blood Transplant (CBT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Bn)
9. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2018 - 2030, (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Pluristem Therapeutics Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Kiadis Pharma
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio,Inc.
- Talaris Therapeutics, Inc.,
- Marker Therapeutics Inc.
- Stempeutics Research Pvt Ltd.
- CBR Systems Inc.
- Priothera Ltd.
- Eurobio Scientific Group
- Otsuka America Pharmaceutical, Inc.
- Pfizer Inc.
- Sanofi
- FUJIFILM Holdings Corporation
11. Section
- References
- Research Methodology
- About us and Sales Contact
